Table 2.
Effects of nicotine administration on mental disorder-related processes in clinical studies.
| Mental disorder | Nicotine treatment | Outcome | Reference |
|---|---|---|---|
| Tobacco addiction | Transdermal patch (21 or 35 mg) | ↗ attention | Lawrence et al. (140), Hong et al. (141) |
| Nasal spray (1 mg) | ↗ attention | Warbrick et al. (142) | |
| Nasal spray (1 mg) | ↗ prospective memory | Rusted and Trawley (143) | |
| Gum (4 mg) | ↗ prospective memory | Jansari et al. (144) | |
| Schizophrenia | Transdermal patch (14, 21, or 35 mg) | ↗ attention | Barr et al. (145), Hong et al. (141) |
| Nasal spray (1 mg) | ↗ PPI | Hong et al. (146) | |
| Subcutaneous injection (12 μg/kg) | ↗ PPI | Postma et al. (147) | |
| ADHD | Transdermal patch 7 mg/kg (non-smokers) or 21 mg/kg (smokers) | ↘ ADHD symptoms | Conners et al. (148), Levin et al. (149), Bekker et al. (150) |
| Transdermal patch (7 mg) | ↘ motor impulsivity | Potter and Newhouse (151, 152), Potter et al. (153) | |
| Major depression | Transdermal patch (17.5 mg) | ↘ depression symptoms | Salin-Pascual et al. (154) |
| OCD | Transdermal patch (17.5 mg) | ↘ compulsion and anxiety | Salin-Pascual and Basanez-Villa (155) |
PPI, prepulse inhibition of startle reflex; ADHD, attention-deficit hyperactivity disorder; OCD, obsessive–compulsive disorder.